Johnson & Johnson

Johnson & Johnson MedTech Celebrates Inaugural National Heart Recovery Awareness Day

20 Feb 2025

Impella patients share stories of heart recovery at reunions, events across the country Launch of Boston’s first hands-only CPR kiosk with American Heart Association

“The surgical devices I design for Johnson & Johnson can help speed healing and save lives”

19 Feb 2025

Meet R&D design engineer Candice Otrembiak at J&J MedTech, who creates high-tech devices that make surgeries more efficient for surgeons and safer for patients.

Johnson & Johnson to Resume U.S. VARIPULSE™ Cases

15 Feb 2025

Investigation found that VARIPULSE™ devices operate as intended Cases being performed in U.S. External Evaluation to resume and Instructions for Use to be updated

Careers at J&J

14 Feb 2025

Working with Johnson & Johnson can change everything—including you. Explore impactful jobs, inclusive employee benefits and how you can join us.

New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

13 Feb 2025

Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions

Johnson & Johnson Statement on Phase 3 E.mbrace Study

13 Feb 2025

Independent, scheduled review finds investigational vaccine regimen lacks efficacy in preventing invasive E. coli disease (IED) No safety signals identified

Johnson & Johnson MedTech Launches CEREGLIDE™ 92 Catheter System for Acute Ischemic Stroke

12 Feb 2025

Next-generation .092” catheter now available in U.S.

Johnson & Johnson to Participate in the 45

04 Feb 2025

New Brunswick, N.J., February 3rd, 2025 – Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will particiaptate in a f

CHMP recommends subcutaneous RYBREVANT

03 Feb 2025

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related r

Johnson & Johnson named a 2025

30 Jan 2025

A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.

View details about the software product Informachine News Trackers